AxoGen, Inc. (NASDAQ:AXGN) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET

Company Participants

Ed Joyce – Director-Investor Relations

Karen Zaderej – Chairman, Chief Executive Officer and President

Pete Mariani – Executive Vice President and Chief Financial Officer

Conference Call Participants

Chris Pasquale – Nephron

Mike Sarcone – Jefferies

Ryan Zimmerman – BTIG

Kyle Rose – Canaccord

David Turkaly – JMP Securities

Operator

Good day ladies and gentlemen. And welcome to the AxoGen Incorporated Reports First Quarter 2023 Financial Results. [Operator Instructions]

At this time it is my pleasure to turn the floor over to your host, Ed Joyce, Director of Investor Relations. Sir, the floor is yours.

Ed Joyce

Thank you, Kate. Good morning everyone.

Joining me on today’s call is Karen Zaderej, AxoGen’s Chairman, Chief Executive Officer and President; and Pete Mariani, Executive Vice President and Chief Financial Officer. Karen will discuss the quarter and our outlook for the year, and Pete will provide an analysis of our financial performance, followed by a question-and-answer session.

Today’s call is being broadcast live via webcast, which is available on the Investors section of the AxoGen’s website. Following the end of the live call, a replay will be available in the Investors section of the company’s website at www.axogeninc.com.

Before we get started, I’d like to remind you that during this conference call, the company will make projections and forward-looking statements including our 2023 financial outlook, timing of our BLA submission, penetration of core accounts, marketing opportunities with nerve applications associated with breast, OMF and the surgical treatment of pain and new products, timing of our APC renovations and balance sheet provisions.

Forward-looking statements are based on current beliefs and assumptions and are not guarantees of future performance and are subject to risks and uncertainties, including, without limitation, the risks and uncertainties reflected in the company’s annual and periodic reports such as hospital staffing issues, regulatory process and approvals, APC renovation, timing and expense, surgeon and product adoption, and market awareness of our products. The forward-looking statements are representative only as of the date they are made and except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

In addition, for a reconciliation of the non-GAAP measures including adjusted core and active account numbers, excluding the impact of Avive purchases, please reference today’s press release and our corporate presentation on the Investors section of the company’s website.